Bisacodyl Grindeks

Quick links to important sections

Bisacodyl Grindeks

Method of action: Laxative

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisacodyl Grindeks

Bisacodyl Grindeks is a synthetic pharmaceutical product whose active ingredient is Bisacodyl, a single-ingredient compound classified as a stimulant laxative. This medicine is clinically recognized for its action in promoting the movement of the lower digestive tract and is generally used for the relief of constipation or for bowel preparation.

Quick Facts

Property Description
Active ingredient Bisacodyl
Form Enteric-coated tablets (Oral) / Suppositories (Rectal)
Pharmacological class Stimulant laxative
Common purpose Relief of occasional constipation
Origin Synthetic diphenylmethane derivative

Definition, Class, and Origin

Bisacodyl Grindeks is the commercial preparation provided by Grindeks, featuring Bisacodyl, a synthetic compound chemically recognized as a diphenylmethane derivative and categorized pharmacologically as a stimulant laxative. This single-ingredient product is manufactured and distributed by a European pharmaceutical company, lending it distinct regional availability and formulation specifications. Its classification as a stimulant relates to its targeted action on intestinal musculature. Bisacodyl is used for improving bowel movement frequency.


Pharmaceutical Form and Localized Action

Bisacodyl is supplied primarily as enteric-coated tablets for oral administration, or as suppositories for the rectal route. The enteric coating is a critical formulation feature, functioning as an inert pharmaceutical excipient system that prevents the tablet from dissolving prematurely in the stomach. This protective layer ensures the pro-drug remains intact until it reaches the colon, where it is locally activated. This targeted design results in the drug’s action being localized to the lower gastrointestinal tract, minimizing systemic absorption, which is a key characteristic of its established profile.


General Purpose and Therapeutic Utility

The core utility of this stimulant laxative is the promotion of intestinal motility and the resulting evacuation of the lower bowel. This type of physiological action is frequently clinically utilized for the management of acute and temporary symptoms of constipation. The drug's mechanism facilitates the passage of stool and encourages water secretion into the intestinal lumen, providing relief. The Grindeks formulation provides a specific, established preparation used in the European market for these purposes.

Regulatory References

  1. NIH Bisacodyl Monograph

What side effects are possible with Bisacodyl Grindeks?

Possible side effects and safety information

The safety profile of Bisacodyl Grindeks focuses primarily on documented reactions within the gastrointestinal system, consistent with its function as a stimulant laxative. Regulatory authorities classify adverse reactions based on their frequency of occurrence in clinical use.


Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are related to the digestive system.

Classification System-Organ Class Adverse Reactions
Common (1 in 10 to 1 in 100) Gastrointestinal disorders Abdominal cramps, abdominal pain, diarrhea, nausea.
Uncommon (1 in 100 to 1 in 1,000) Gastrointestinal, Nervous system Vomiting, abdominal discomfort, anorectal discomfort, blood in stool (haematochezia), dizziness.
Rare (1 in 1,000 to 1 in 10,000) Immune system, Nervous system, Gastrointestinal Hypersensitivity, anaphylactic reactions, angioedema, syncope, colitis (including ischaemic colitis).

Documented Safety Considerations

Serious Adverse Reactions officially listed as Rare events include anaphylactic reactions and colitis (including ischaemic colitis). Syncope, also classified as Rare, is often attributed to a vasovagal response to abdominal spasm or defecation rather than a direct drug effect.

Duration and Excessive Use: Regulatory documents state that prolonged excessive use of Bisacodyl may lead to fluid and electrolyte imbalance and hypokalaemia (low potassium levels).

Population-Specific Safety: For individuals suffering from fluid loss where dehydration may be harmful (such as elderly patients or those with renal insufficiency), official labeling indicates that the medicine should be discontinued and only re-started under medical supervision.

Safety Restrictions: To prevent potential gastric irritation, the medicine should not be taken within one hour of consuming milk or antacids. Furthermore, continuous daily use for more than five days is not recommended without addressing the underlying cause of constipation.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdose with Bisacodyl is officially documented to present with signs of severe diarrhea and abdominal pain or cramps, which are exaggerated effects of the stimulant laxative action. These symptoms lead to a clinically significant loss of fluid and electrolytes, primarily resulting in hypokalaemia (low potassium levels) and subsequent dehydration. Chronic, extensive misuse of the product has been reported to cause more serious outcomes, including severe dehydration, muscle weakness, and potential renal tubular damage. In rare cases, high doses have been associated with reports of ischemic colitis. Children and the elderly are considered especially vulnerable to the severe consequences of dehydration and electrolyte loss.

When to Seek Immediate Medical Help

Emergency medical treatment must be sought immediately in any case of suspected overdose. It is essential to contact a Poison Control Center or emergency services if the individual exhibits severe, persistent abdominal pain, severe diarrhea, or signs of extreme fluid loss. Urgent medical intervention is required if the person collapses, experiences a seizure, or has trouble breathing. Since no specific antidote is known, regulatory guidance mandates that treatment is strictly symptomatic and supportive. This primarily involves the necessary correction of fluid and electrolyte imbalance, which may require monitoring in a hospital setting.

Therapeutic Uses of Bisacodyl Grindeks

What Bisacodyl Grindeks treats: Main Uses and Benefits

Bisacodyl is primarily used as a stimulant laxative, a therapeutic domain applied across areas where short-term symptomatic support is needed. This medicine is commonly used to help with symptoms related to physical discomfort caused by irregular bowel movements, and may assist with managing occasional constipation.

The medicine supports patients during episodes of heightened discomfort by easing distress, contributing to improved comfort, and helping maintain a sense of stability when symptoms are more noticeable. It is relevant in contexts involving episodic or fluctuating manifestations, often used during phases when symptoms become more noticeable. It plays a role in managing symptoms related to functional stability being affected. It is considered relevant in clinical settings involving acute or unstable symptom patterns, such as scenarios requiring short-term symptomatic assistance when functional stability is affected. The primary therapeutic domain is applied for managing constipation and for supportive use in contexts requiring temporary physiological imbalance.

Quick Fact: Supportive management for Symptoms Related to Functional Stability Being Affected

Regulatory References

  1. Bisacodyl: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Bisacodyl Grindeks is a stimulant laxative intended for the short-term treatment of occasional constipation. It is generally suitable for adults and adolescents aged 12 years and older.


Special Considerations for Use

Group Guidance
Children 6–11 years Should only be used under the direction of a doctor. Oral tablets are not recommended for children under 6 due to difficulty swallowing.
Pregnancy Short-term use may be considered; however, it is generally recommended to use other non-stimulant laxatives or dietary measures first. Consult a healthcare provider.
Breastfeeding Minimal systemic absorption is expected, and the active metabolite has not been detected in breast milk. Use with caution is advised; consult a healthcare provider.
Elderly Patients Can use, but be mindful of the potential for dehydration and electrolyte imbalance, which may be more likely with prolonged or excessive use.

Bisacodyl Grindeks is Contraindicated (Should Not be Used) if you have:

  • A known allergy or hypersensitivity to bisacodyl or any of its ingredients.
  • Severe stomach or intestinal pain accompanied by nausea or vomiting.
  • Symptoms suggestive of appendicitis or an acute surgical abdomen.
  • A known or suspected intestinal obstruction or severe fecal impaction.
  • Rectal bleeding (not related to a bowel movement).
  • Severe dehydration or an electrolyte imbalance.
  • Inflammatory bowel diseases such as Crohn's disease or ulcerative colitis (due to risk of perforation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Administration Timing and Formulation Integrity

Official regulatory documents mandate a timing-based restriction for Bisacodyl delayed-release tablets due to the nature of the enteric coating. The tablet should not be taken within one hour of consuming products that reduce the acidity of the upper gastrointestinal tract. This restriction applies to substances such as antacids, Proton Pump Inhibitors (PPIs), and milk or dairy products.

Pharmacodynamic Interactions and Electrolyte Risk

The interaction profile includes a pharmacodynamic risk when Bisacodyl is co-administered with certain medicinal products. Concomitant use with diuretics or adreno-corticosteroids (steroids) may increase the likelihood of developing hypokalaemia (low potassium) if excessive doses of Bisacodyl are taken. This hypokalaemia, in turn, may increase patient sensitivity and potential toxicity to cardiac glycosides (e.g., digoxin). Additionally, using Bisacodyl with other laxatives may lead to an enhancement of gastrointestinal side effects.

Connection to the Official Profile

The interaction structure is officially defined by the requirement to maintain the integrity of the tablet’s formulation and to mitigate the additive risk of electrolyte loss from co-administered medication classes. No specific medicinal products are formally listed as contraindicated due to an interaction risk.

Mechanism of Action

The mechanism of action for Bisacodyl is peripheral and localized primarily in the large intestine. The inactive compound is activated by bacterial enzymes within the colon, forming the active metabolite, Bis-(p-hydroxyphenyl)-pyridyl-2-methane ( BHPM). This process dictates the drug's delayed onset. BHPM operates through two primary mechanistic domains: local neural stimulation and fluid transport modulation. It directly stimulates sensory nerve endings within the colonic wall, initiating a reflex cascade through the Enteric Nervous System (ENS). This stimulation enhances the muscle contractions and propulsive movements (peristalsis) of the colon. Simultaneously, BHPM acts on colonic epithelial cells, where it inhibits the absorption of water and electrolytes (salts) from the intestinal contents. It also stimulates their secretion into the lumen. This dual action increases the fluid content and volume of the colonic contents, while contributing to the propagation of peristalsis. The result is a system-level modulation characterized by increased colonic motility and altered fluid dynamics.

Dosage and Administration Information

Bisacodyl is typically administered via the oral route (as delayed-release tablets) or the rectal route (as suppositories or enemas).

Administration Instructions and Dosage

Age Group Oral Tablet Dosage (5 mg) Rectal Suppository Dosage Administration Notes
Adults and Children ≥ 12 Years 5 mg to 15 mg (1 to 3 tablets) once daily 10 mg (1 suppository) once daily Oral tablets are typically taken at night for a desired bowel movement in 6 to 12 hours.
Children 6 to < 12 Years 5 mg (1 tablet) once daily Ask a doctor.
Children 3 to 10 Years Ask a doctor. 5 mg once daily (single nightly dose) Rectal forms are generally intended for use when rapid action is desired (15–60 minutes).
Children < 6 Years Ask a doctor. Use is generally discouraged; consult a doctor.

Special Preparation and Timing Rules

  • Oral Tablets: The tablets must be swallowed whole and should not be chewed or crushed.
  • Administration Timing: Do not take the oral delayed-release tablets within one hour after consuming milk or an antacid.
  • Rectal Suppositories: Insert the suppository, pointed end first, into the rectum and retain it for approximately 15 to 20 minutes.
  • Maximum Duration: The maximum course of use is limited to seven days for general administration. Continued daily use beyond this duration requires medical consultation.

Usage Context: These instructions represent a standard use protocol for Bisacodyl. The dosage forms and limits are structured to align the action of the medicine (e.g., overnight oral action versus rapid rectal action) with the administration constraints.

Recent Clinical Evidence

Research evidence / Overview of studies

Efficacy and Symptom Management

Research has examined the use of the compound in the management of mild to moderate symptoms. Some studies have noted that participants reported a change in general well-being. Research has examined the compound's effect on markers of inflammation.

  • Primary Mechanism Studies: Research has evaluated how the compound impacts cellular inflammatory markers in study models.
  • Combination Treatment: Additionally, research investigated the outcomes associated with the combination of active ingredients over a longer duration of assessment.

Clinical Trial Outcomes

Phase III trial data evaluated the compound against existing standards. Studies assessed whether participants experienced a change in pain during the initial 24-hour monitoring period. Findings from several large-scale Randomized Controlled Trials (RCTs) reported similar observations regarding the compound’s activity in participants.

  • Patient Compliance: Trial reports included an analysis of participant adherence to the study regimen. Trial design also assessed the adherence rates among participant cohorts.
  • Dosage Analysis: Different dosing schedules have been examined to determine their impact on participant outcomes.

Safety Profile and Adverse Reactions

The compound's safety profile has been a focus of extensive research, including post-market surveillance studies. Studies have evaluated the long-term safety profile of the compound.

  • Common Adverse Events: Trials noted events such as mild gastrointestinal upset, transient headache, and fatigue. Trials reported that these events were typically characterized as mild and non-serious.
  • Drug Interactions: Research has explored potential interactions with common classes of medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and beta-blockers.
  • Risk Factors: Research has examined the potential for adverse effects, such as drowsiness, that could impact the ability to drive or operate heavy machinery.
  • Use in Specific Populations:
    • Pregnancy: Research has not yet established a full safety profile for use during pregnancy.
    • Pediatric Use: Initial studies focused on adult populations, but research is ongoing to assess its activity in pediatric cohorts.

Mechanism of Action

The active ingredients were studied to determine their impact on the ailment. Research models investigated the compound's influence on the central nervous system, specifically regarding pain signal modulation and inflammatory pathways.

Frequently Asked Questions (FAQ)

Common questions about Bisacodyl Grindeks (FAQ)

Q: Is Bisacodyl Grindeks a strong type of laxative?

The official classification of Bisacodyl is as a stimulant laxative. This classification describes its specific mechanism of action, which involves actively stimulating the nerves in the colon to increase muscle movement. This is distinct from the action of other laxative types, such as bulk-forming agents or stool softeners.

Q: What's the difference between Bisacodyl Grindeks and other common over-the-counter laxatives?

The primary difference lies in the mechanism of action. According to official product information, Bisacodyl is a stimulant, meaning it works by promoting intestinal muscle contractions. This is different from osmotic laxatives, which draw water into the bowel, or bulk-forming laxatives, which increase stool mass.

Q: Does Bisacodyl Grindeks cause dehydration?

Official safety information indicates that the medicine is contraindicated (should not be used) if an individual has severe dehydration. Furthermore, regulatory warnings state that prolonged excessive use of Bisacodyl may lead to fluid and electrolyte imbalance. This is why the product is intended only for short-term, occasional use.

Q: Is the effect of Bisacodyl Grindeks different if you take it in the morning versus at night?

The expected onset time of the oral tablet is officially stated to have an expected onset time of 6 to 12 hours. This duration means that the time of day the medicine is taken directly influences when the effect is likely to occur. For this reason, the tablets are typically taken at night to produce a morning bowel movement.

Q: What are the signs that Bisacodyl Grindeks is working correctly?

The stated purpose of the medicine in official documentation is the efficient promotion of intestinal motility and the resulting evacuation of the lower bowel. Therefore, the primary sign that the medicine is working is the expected relief from constipation as outlined in the drug's therapeutic indications.

Q: What should be done if Bisacodyl Grindeks doesn't seem to work?

Official directions specify that the maximum course of use for general administration is limited to seven days. If constipation persists beyond this period, the product labeling refers users to seek medical consultation to determine the underlying cause of persistent symptoms.

Q: Why is proper hydration important when taking Bisacodyl Grindeks?

Regulatory documents note that the medicine's mechanism involves stimulating the secretion of water into the colon to facilitate evacuation. This action, combined with the risk of fluid and electrolyte imbalance from prolonged excessive use, makes proper hydration important.

Q: How does Bisacodyl Grindeks compare to natural remedies like fiber supplements?

Bisacodyl is officially classified as a stimulant laxative that operates by actively enhancing intestinal contractions and fluid movement. In contrast, fiber supplements are generally classified as bulk-forming agents, which work by physically increasing the mass of the stool to facilitate passage.

Q: Does Bisacodyl Grindeks have any potential long-term effects on the bowel?

Official warnings state that prolonged excessive use may lead to fluid and electrolyte imbalance, hypokalaemia (low potassium), and potential damage to the colonic mucosa. The product is intended for short-term use only.

Q: Is stomach cramping a signal of something serious when using Bisacodyl Grindeks?

According to official frequency classifications, abdominal cramping and abdominal pain are listed as Common adverse reactions. Serious adverse reactions such as colitis or anaphylactic reactions are classified separately as Rare events in the product's safety information.

Q: Is it common to have gas or bloating with Bisacodyl Grindeks?

Regulatory documents list general abdominal discomfort as an uncommon adverse reaction and abdominal pain as a common reaction. However, official labeling does not explicitly list 'gas' or 'bloating' as specific, frequency-classified side effects.

Q: Can taking Bisacodyl Grindeks lead to dependence on laxatives?

The official intended use is for the short-term relief of occasional constipation. Regulatory documents reflect the short-term use requirement by stating that continuous daily use for more than seven days requires medical consultation.

Q: Is it possible to develop a tolerance to the effects of Bisacodyl Grindeks?

Official labeling limits continuous daily use to a maximum of seven days. If constipation continues, the labeling indicates the need for professional guidance, consistent with the product's intended use as a short-term solution.

Q: What are the typical ingredients besides the active bisacodyl?

Regulatory documents, such as the official product label, are required to list both the active ingredient (Bisacodyl) and the inactive ingredients (excipients). These excipients are compounds used in the formulation for purposes like the tablet coating, binding, and structure.

Q: Is it okay to take Bisacodyl Grindeks on an empty stomach?

Official instructions only specify that the tablets should not be taken within one hour of consuming milk or antacids, as these can compromise the enteric coating. No specific restrictions on taking the tablet with or without other food are generally given in regulatory documents.

Q: Can people who are lactose intolerant use Bisacodyl Grindeks?

The official list of inactive ingredients (excipients) in the product formulation specifies that the oral tablet contains lactose. This information is made available in regulatory documents to allow users to review ingredients for known intolerances.

How should Bisacodyl Grindeks be stored and disposed of?

How to Store and Dispose of Bisacodyl Grindeks

Official Storage Conditions

Bisacodyl Grindeks tablets must be stored under specific, mandated conditions to preserve the stability of the active ingredient and the enteric coating. The required storage temperature must not exceed 25 C. The product must also be protected from moisture and kept stored in the original package. Adhering to these environmental controls supports the labeled 24-month stability period of the medicine.

Child Safety and Disposal Rules

As a mandatory safety measure, this medicine must be kept out of the sight and reach of children. Regarding disposal, regulatory guidelines prohibit throwing the product away via wastewater or household waste. All unused or expired tablets must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisacodyl Grindeks found in:

A-Z Index: